Agios Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-	673.73	-352.09	-231.8	1,605
Depreciation & Amortization	-	5.65	6.62	8.56	9.24
Loss (Gain) From Sale of Assets	-	-200.04	0.55	-0.05	0.01
Loss (Gain) From Sale of Investments	-	-14.65	-5.08	-1.2	6.95
Stock-Based Compensation	-	42.85	44.77	49.3	53.51
Other Operating Activities	-	-877.61	28.22	-117.86	-1,952
Change in Accounts Receivable	-	-1.3	-0.6	-2.21	-
Change in Inventory	-	-8.54	-10.58	-8.49	-
Change in Accounts Payable	-	6.6	-8.73	3.44	1.86
Change in Income Taxes	-	0.87	-	-	-
Change in Other Net Operating Assets	-	-17.4	0.86	-9.17	-38.69
Operating Cash Flow	-	-389.84	-296.06	-309.48	-407.32
Capital Expenditures	-	-1.69	-1	-4.88	-5.74
Sale of Property, Plant & Equipment	-	0.04	1.33	0.96	-
Divestitures	-	200	-	-	-
Sale (Purchase) of Intangibles	-	-	-17.5	-	-
Investment in Securities	-	-724.05	256.75	115.39	-548.42
Other Investing Activities	-	889.14	-	131.78	1,803
Investing Cash Flow	-	363.44	239.58	243.26	1,249
Long-Term Debt Repaid	-	-	-	-0.33	-0.58
Net Debt Issued (Repaid)	-	-	-	-0.33	-0.58
Issuance of Common Stock	-	14.44	5.43	2.68	37.3
Repurchase of Common Stock	-	-	-	-	-802.49
Financing Cash Flow	-	14.44	5.43	2.35	-765.77
Net Cash Flow	-	-11.96	-51.05	-63.87	75.69
Free Cash Flow	-	-391.53	-297.06	-314.36	-413.06
Free Cash Flow Margin	-	-1072.73%	-1107.49%	-2207.58%	-
Free Cash Flow Per Share	-	-6.76	-5.34	-5.74	-6.83
Cash Income Tax Paid	-	43.15	1.57	-	16.08
Levered Free Cash Flow	-	-222.83	-215.06	-195.32	-198.29
Unlevered Free Cash Flow	-	-222.83	-215.06	-195.32	-198.29
Change in Working Capital	-	-19.77	-19.06	-16.43	-36.82

Source: S&P Global Market Intelligence. Standard template. Financial Sources.